m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05949
 [1]
m6A modification FAM225A FAM225A METTL3 Methylation : m6A sites Indirect Inhibition Non-coding RNA miR-1275 ITGB3  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Family with sequence similarity 225 member A (FAM225A)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator MicroRNA 1275 (MIR1275) LncRNA View Details
Regulated Target Integrin subunit beta 3 (ITGB3) View Details
Crosstalk Relationship m6A  →  ncRNA Inhibition
Crosstalk Mechanism m6A regulators indirectly modulate the functionality of ncRNAs through downstream signaling pathways
Crosstalk Summary Silencing METTL3 decreases Family with sequence similarity 225 member A (FAM225A) RNA stability, which serves as the ceRNA for sponging both miR-590-3p and MIR1275, increasing the levels of their target integrin beta3 (Integrin subunit beta 3 (ITGB3)), finally stimulating FAK/PI3K/Akt signaling. miR-590-3p has been reported as a tumor suppressor in cholangiocarcinoma and hepatocellular carcinoma and miR-1275 can inhibit NPC cell growth and suppress hepatocellular carcinoma cell proliferation.
Responsed Disease Hepatocellular carcinoma ICD-11: 2C12.02
 Disease Info 
Pathway Response PI3K-Akt signaling pathway hsa04151
Cell Process mRNA stability
Cell proliferation
Cell invasion
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Integrin subunit beta 3 (ITGB3) 77 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name XEMILOFIBAN Discontinued in Phase 3 [2]
Synonyms
Xemilofiban [INN]; 149820-74-6; UNII-P614JI3IYK; SC-54684A; SC 54684A; P614JI3IYK; SC-54684; CHEMBL76098; Ethyl-3S-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-4-pentynoate; C18H22N4O4; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, ethyl ester, (S)-; CS-551; AC1Q5MFX; AC1L1U8F; SCHEMBL50663; DTXSID60164410; ZINC1535967; BDBM50083460; KB-81502; LS-102305; ethyl(3s)-3-[3-[(p-amidinophenyl)carbamoyl]propionamido]-4-pentynoate
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 60957
TTD: D07EXV
 Compound Name DMP-802 Discontinued in Phase 1 [3]
Synonyms
CHEMBL117989; CHEMBL275611; SCHEMBL7748060; BDBM50075566; (S)-3-{2-[(R)-3-(4-Carbamimidoyl-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-2-(3,5-dimethyl-isoxazole-4-sulfonylamino)-propionic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9812185
TTD: D0K0NP
 Compound Name L-709780 Terminated [4]
Synonyms
CHEMBL32960; BDBM50078448; l709780; N-[2-[2-(4-Piperidinyl)ethyl]-3-oxoisoindoline-5-ylcarbonyl]-beta-alanine; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid(L-709780); 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-propionic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9885190
TTD: D03GCN
 Compound Name Ro-43-8857 Terminated [3]
Synonyms
CHEMBL290497; SCHEMBL8381416; BDBM50003852; alpha,alpha'-[[4-[[Methyl(4-amidinobenzoyl)amino]acetyl]-o-phenylene]bis(oxy)]diacetic acid; (4-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid; (5-{2-[(4-Carbamimidoyl-benzoyl)-methyl-amino]-acetyl}-2-carboxymethoxy-phenoxy)-acetic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9933077
TTD: D03QHI
 Compound Name SKF-107260 Terminated [5]
Synonyms
F 107260; CHEMBL18734; [(7s,13s)-13-{3-[(diaminomethylidene)amino]propyl}-14-methyl-6,9,12,15-tetraoxo-6,7,8,9,10,11,12,13,14,15-decahydro-5h-dibenzo[c,p][1,2,5,8,11,14]dithiatetraazacycloheptadecin-7-yl]acetic acid; 136620-00-3; Skf 107260; F-107260; AC1L4UPG; AC1Q6GV5; Cyclo-S,S-(mba-(N(alpha)-Me)arg-gly-asp-man); CTK4C0386; DTXSID70159857; BDBM50036088; BDBM50230131; Cyclo-S,S-(2-mercaptobenzoyl-N(alpha)-methylarginyl-glycyl-aspartyl-2-mercaptophenylamide)
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 164393
TTD: D08CQL
 Compound Name L-738167 Terminated [3]
Synonyms
CHEMBL298655; L 738167; 163212-43-9; AC1L4BHI; SCHEMBL609722; DTXSID30167534; YLFFZEQHDMFOEC-NRFANRHFSA-N; BDBM50058239; L-Alanine, N-((4-methylphenyl)sulfonyl)-3-(((5,6,7,8-tetrahydro-4-oxo-5-(2-(4-piperidinyl)ethyl)-4H-pyrazolo(1,5-a)(1,4)diazepin-2-yl)carbonyl)amino)-; 3-{[4-Oxo-5-(2-piperidin-4-yl-ethyl)-5,6,7,8-tetrahydro-4H-1,5,8a-triaza-azulene-2-carbonyl]-amino}-2-(toluene-4-sulfonylamino)-propionic acid (L-738167)
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 153986
TTD: D08LIG
 Compound Name DMP-757 Terminated [6]
Synonyms
CHEMBL65617; BDBM50285199; [(5S,11S,14S)-11-(3-Guanidino-propyl)-14-isopropyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-bicyclo[15.3.1]henicosa-1(20),17(21),18-trien-5-yl]-acetic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10031011
TTD: D0U4ZY
 Compound Name Ro-43-5054 Terminated [3]
Synonyms
CHEMBL117775; SCHEMBL7306316; BDBM50092124; 2-{2-[3-(4-Carbamimidoyl-benzoylamino)-propionylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid (Ro 43-5054)
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44343754
TTD: D0Z0XQ
 Compound Name SC-47643 Terminated [7]
Synonyms
CHEMBL129921; BDBM50035970; 3-(8-Guanidino-octanoylamino)-N-[2-(4-methoxy-phenyl)-ethyl]-succinamic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 124392
TTD: D0G9BX
 Compound Name SB-223245 Terminated [8]
Synonyms
CHEMBL50106; SCHEMBL245523; BDBM50059133; {7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid; {(S)-7-[(1H-Benzoimidazol-2-ylmethyl)-methyl-carbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl}-acetic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9823503
TTD: D0LT1S
 Compound Name L-739758 Investigative [3]
Synonyms
CHEMBL78760; BDBM50078437; 3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-739758); (S)-3-{[5-(2-Piperidin-4-yl-ethyl)-thieno[2,3-b]thiophene-2-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid; (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[5-[2-(4-piperidinyl)ethyl]thieno[2,3-b]thiophen-2-yl]carbonylamino]propanoic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9958398
TTD: D01XUU
 Compound Name ISIS 25237 Investigative [9]
External Link
TTD: D02MYZ
 Compound Name ROXIFIBAN Investigative [3]
Synonyms
UNII-Q476FMZ72G; DMP754; 170902-47-3; CHEMBL18301; Q476FMZ72G; DMP-754; Roxifiban [INN]; AC1L42MF; SCHEMBL344302; DTXSID70168969; BDBM50075579; methyl (2S)-2-(butoxycarbonylamino)-3-[[2-[(5R)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]propanoate; L-Alanine, 3-(((3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methyl ester, (R)-; L-Alanine, 3-((((5R)-3-(4-(aminoiminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methy
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 177230
TTD: D04BHL
 Compound Name RWJ-53419 Investigative [10]
Synonyms
CHEMBL421547; BDBM50104598; 2-Benzyloxycarbonylamino-3-{[(R)-1-(3-piperidin-4-yl-propionyl)-piperidine-3-carbonyl]-amino}-propionic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44322318
TTD: D04XTP
 Compound Name L-750034 Investigative [11]
Synonyms
CHEMBL326492; BDBM50076058; 2-((S)-Benzenesulfonylamino)-3-(4-piperazin-1-yl-benzoylamino)-propionic acid; 2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid(L-750034); (S)-2-Benzenesulfonylamino-3-(4-piperazin-1-yl-benzoylamino)-propionic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11743533
TTD: D05AGK
 Compound Name L-756568 Investigative [3]
Synonyms
CHEMBL96097; BDBM50092097; (S)-2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid; 2-Benzenesulfonylamino-3-{[5-(piperidin-4-ylmethoxy)-1H-indole-2-carbonyl]-amino}-propionic acid(L-756568)
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9805998
TTD: D06LHH
 Compound Name SC-54701A Investigative [12]
Synonyms
UNII-TN585Y92BI; SC-54701; CHEMBL311572; TN585Y92BI; Xemilofiban acid; Xemilofiban acid [MI]; SCHEMBL7080314; BDBM50031565; 4-Pentynoic acid, 3-((4-((4-(aminoiminomethyl)phenyl)amino)-1,4-dioxobutyl)amino)-, (3S)-; 149193-61-3; (S)-3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid ethyl ester; 3-[3-(4-Carbamimidoyl-phenylcarbamoyl)-propionylamino]-pent-4-ynoic acid (SC-54701A)
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9862322
TTD: D08RLR
 Compound Name L-734115 Investigative [3]
Synonyms
CHEMBL40502; BDBM50058236; N-(Butylsulfonyl)-3-[[4,5,6,7-tetrahydro-4-oxo-5-[2-(4-piperidinyl)ethyl]pyrazolo[1,5-a]pyrazin]-2-ylcarbonylamino]-L-alanine; (S)-2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid; 2-(Butane-1-sulfonylamino)-3-{[4-oxo-5-(2-piperidin-4-yl-ethyl)-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carbonyl]-amino}-propionic acid(L-734115)
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9913833
TTD: D0C8LA
 Compound Name SB-207043 Investigative [5]
Synonyms
CHEMBL606910
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 52942958
TTD: D0M7KS
 Compound Name ISIS 196103 Investigative [9]
External Link
TTD: D0Q2ZS
 Compound Name L-746233 Investigative [3]
Synonyms
CHEMBL79294; BDBM50078442; 3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid(L-746233); (2S)-2-[(3-Pyridinyl)sulfonylamino]-3-[[2-[2-(4-piperidinyl)ethyl]-3-oxoisoindolin-5-yl]carbonylamino]propanoic acid; (S)-3-{[3-Oxo-2-(2-piperidin-4-yl-ethyl)-2,3-dihydro-1H-isoindole-5-carbonyl]-amino}-2-(pyridine-3-sulfonylamino)-propionic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10324223
TTD: D0S8DT
 Compound Name L-767679 Investigative [3]
Synonyms
CHEMBL57886; L 767679; AC1L42P7; BDBM50054538; 182198-53-4; 3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid(L-767679); (S)-3-[2-(1-Oxo-7-piperazin-1-yl-3,4-dihydro-1H-isoquinolin-2-yl)-acetylamino]-pent-4-ynoic acid; (3S)-3-[[2-(1-oxo-7-piperazin-1-yl-3,4-dihydroisoquinolin-2-yl)acetyl]amino]pent-4-ynoic acid; 4-Pentynoic acid, 3-(((3,4-dihydro-1-oxo-7-(1-piperazinyl)-2(1H)-isoquinolinyl)acetyl)amino)-, (3S)-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 177364
TTD: D0W5ZK
 Compound Name C(RGDfF) Investigative [13]
Synonyms
CHEMBL380434
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10699123
TTD: D00YBU
 Compound Name Ac-Asp-Arg-Leu-Asp-Ser-OH Investigative [14]
Synonyms
CHEMBL238484; Acetyl-Asp-Arg-Leu-Asp-Ser-OH; ZINC28869420
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11764797
TTD: D01AXA
 Compound Name C[-Arg-Gly-Asp-Acpca21-] Investigative [15]
Synonyms
CHEMBL534711
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11613122
TTD: D01BZH
 Compound Name C-[-Arg-Gly-Asp-Acpca32-] Investigative [15]
Synonyms
CHEMBL556402
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11583738
TTD: D01MGI
 Compound Name 3-(3-(carbamoyl)benzamido)propanoic acid Investigative [16]
Synonyms
CHEMBL219603
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44418280
TTD: D01ZJF
 Compound Name Cyclo-[-Arg-Gly-Asp-Amp22-] Investigative [17]
Synonyms
CHEMBL406912
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 24822283
TTD: D03KLT
 Compound Name Cyclo-[-Arg-Gly-Asp-Amp21-] Investigative [17]
Synonyms
CHEMBL411863; BDBM50372589
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 24822953
TTD: D03YLY
 Compound Name Cypate-[(RGD)2-NH2]2 Investigative [18]
MOA Inhibitor
External Link
CID: 91936295
TTD: D04MCL
 Compound Name C[-Arg-Gly-Asp-Acpca35-] Investigative [15]
Synonyms
CHEMBL534713
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11540460
TTD: D04WVG
 Compound Name C[RGDf-(S)-alpha-TfmV] Investigative [13]
Synonyms
CHEMBL203693
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10416726
TTD: D05EWB
 Compound Name Cyclo-[-Arg-Gly-Asp-Amp26-] Investigative [17]
Synonyms
CHEMBL406680
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 24822444
TTD: D05GXK
 Compound Name E[c(RGDyK)]2 Investigative [19]
Synonyms
CHEMBL414385
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44388431
TTD: D05MJG
 Compound Name C-[-Arg-Gly-Asp-Acpca30-] Investigative [15]
Synonyms
CHEMBL540622
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11712622
TTD: D05VEC
 Compound Name C[-Arg-Gly-Asp-Acpca36-] Investigative [15]
Synonyms
CHEMBL557157
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11518823
TTD: D06JLN
 Compound Name Gly-Arg-Gly-Asp-Ser Investigative [20]
Synonyms
96426-21-0; GRGDS; glycyl-arginyl-glycyl-aspartyl-serine; H-Gly-Arg-Gly-Asp-Ser-OH; CHEMBL417553; L-Serine, N-(N-(N-(N2-glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-; GRGDS Peptide; C17H30N8O9; AC1L3XCA; NH2-Gly-Arg-Gly-Asp-Ser; SCHEMBL17440322; RGNVSYKVCGAEHK-GUBZILKMSA-N; HY-P0295; ZINC13455558; MFCD00076459; BDBM50414896; BDBM50006330; AKOS030622941; NCGC00167212-01; Gly-Arg-Gly-Asp-Ser, > LS-178299; FT-0772116; L-Serine,glycyl-L-arginylglycyl-L-a-aspartyl-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 123811
TTD: D06LKH
 Compound Name Cyclo-[-Arg-Gly-Asp-Amp25-] Investigative [17]
Synonyms
CHEMBL270690
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 24822784
TTD: D07QJD
 Compound Name C(RGDfMeF) Investigative [13]
Synonyms
CHEMBL383747
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44408450
TTD: D07UOF
 Compound Name C[RGDf-(R)-alpha-TfmV] Investigative [13]
Synonyms
CHEMBL203077
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11505585
TTD: D08CFM
 Compound Name C(Arg-Gly-Asp-D-Phe-Val) Investigative [21]
Synonyms
CHEMBL383412
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44411994
TTD: D08DSG
 Compound Name C-[-Arg-Gly-Asp-Acpca31-] Investigative [15]
Synonyms
CHEMBL534934
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11533023
TTD: D09PLA
 Compound Name RGDechi Investigative [21]
MOA Inhibitor
External Link
CID: 91936353
TTD: D0D4QZ
 Compound Name 3-(3-(benzamido)-5-nitrobenzamido)propanoic acid Investigative [16]
Synonyms
CHEMBL218226
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44418282
TTD: D0G7QJ
 Compound Name Cyclo(RGDfV) (control) Investigative [18]
Synonyms
CHEMBL206344
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44409460
TTD: D0G8JI
 Compound Name C[RGDf-(R)-N-Me-alpha-TfmF] Investigative [13]
Synonyms
CHEMBL381590
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11643340
TTD: D0H4EK
 Compound Name ISONIPECOTAMIDE Investigative [22]
Synonyms
Piperidine-4-carboxamide; 39546-32-2; 4-Piperidinecarboxamide; Hexahydroisonicotinamide; 4-carbamoylpiperidine; UNII-CZE2810T4X; CZE2810T4X; DPBWFNDFMCCGGJ-UHFFFAOYSA-N; Piperidine-4-carboxylic acid amide; MFCD00038012; 4-Piperdinecarboxamide; Isonipecotamide, 98%; piperidin-4-carboxamid; iso nipecotamide; iso-nipecotamide; Isonipecotinamide; Piperidine-4-carboxylicacidamide; NSC82318; EINECS 254-501-6; NSC 82318; ISONIPECTOAMIDE; ACMC-20aipw; PubChem9754; Isonipecotic acid amide; 4-piperidine-carboxamide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 3772
TTD: D0H4MB
 Compound Name C[RGDf-(S)-alpha-TfmF] Investigative [13]
Synonyms
CHEMBL204309
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9831456
TTD: D0I5BY
 Compound Name CYCLORGDFV Investigative [23]
Synonyms
cyclo(Arg-Gly-Asp-D-Phe-Val); CHEMBL411941; cyclo[Arg-Gly-Asp-D-Phe-Val]; Cyclo(-Arg-Gly-Asp-D-Phe-Val); 137813-35-5; c-[-Arg-Gly-Asp-fV-]; c[Arg-Gly-Asp-(R)-Phe-Val]; cyclo-(Arg-Gly-Asp-D-Phe-Val); Cyclo(Arg-Gly-Asp-D-Phe-Val-); cyclo(-Arg-Gly-Asp-D-Phe-Val-); BDBM50237601; ZINC17655303; NCGC00167283-01; [(2S,5R,8S,11S)-5-Benzyl-11-(3-guanidino-propyl)-8-isopropyl-3,6,9,12,15-pentaoxo-1,4,7,10,13pentaaza-cyclopentadec-2-yl]-acetic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9851104
TTD: D0ID6U
 Compound Name Cyclo-[-Arg-Gly-Asp-Amp28-] Investigative [17]
Synonyms
CHEMBL270683
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 24824620
TTD: D0J6SP
 Compound Name E[c(RGDyK)]2-PTX conjugate Investigative [19]
MOA Inhibitor
External Link
CID: 91933274
TTD: D0K5DM
 Compound Name Cypate-[(RGD)3-NH2]1 Investigative [18]
MOA Inhibitor
External Link
CID: 91936298
TTD: D0L2PQ
 Compound Name C[-Arg-Gly-Asp-Acpca19-] Investigative [15]
Synonyms
CHEMBL539338
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11569720
TTD: D0LF7W
 Compound Name Gly-Arg-Gly-Asp-Ser-Pro-Lys Investigative [24]
Synonyms
Grgdspk; 111119-28-9; Glycyl-arginyl-glycyl-aspartyl-seryl-prolyl-lysine; CHEMBL58763; AC1L2XSM; SCHEMBL891576; DTXSID20149506; HY-P0322; BDBM50079446; ZINC38989354; MFCD00076462; AKOS027382824; N2-(1-(N-(N-(N-(N2-Glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-L-seryl)-L-prolyl)-L-lysine; NCGC00167196-01; FT-0773649; Gly-Arg-Gly-Asp-Ser-Pro-Lys, > glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine; L-Lysine,glycyl-L-arginylglycyl-L-a-aspartyl-L-seryl-L-prolyl-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 130667
TTD: D0LV6B
 Compound Name C[RGDf-(R)-alpha-TfmF] Investigative [13]
Synonyms
CHEMBL381589
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11636164
TTD: D0M0BN
 Compound Name C[RGDf-(S)-N-Me-alpha-TfmF] Investigative [13]
Synonyms
CHEMBL413574
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10372586
TTD: D0M6NQ
 Compound Name Cypate-[(RGD)4-NH2]2 Investigative [18]
MOA Inhibitor
External Link
CID: 91936297
TTD: D0N9NA
 Compound Name C[-Arg-Gly-Asp-Acpca34-] Investigative [15]
Synonyms
CHEMBL534933
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11584047
TTD: D0O6DN
 Compound Name Cyclo-[-Arg-Gly-Asp-Amp24-] Investigative [17]
Synonyms
CHEMBL437072
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 24823110
TTD: D0O9FL
 Compound Name Cypate-[(RGD)2-NH2]1 Investigative [18]
Synonyms
CHEMBL438186
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44409497
TTD: D0P4RB
 Compound Name N-(3,5-dichlorophenyl)imidodicarbonimidic diamide Investigative [25]
Synonyms
CHEMBL40929; 1672-93-1; Imidodicarbonimidic diamide, N-(3,5-dichlorophenyl)-; 1-(diaminomethylidene)-2-(3,5-dichlorophenyl)guanidine; AC1LBJDA; Maybridge1_007061; SCHEMBL891475; CTK7D2196; CTK0E5441; DTXSID50339817; 1-(3,5-dichlorophenyl)biguanide; BUXACHZAYWAZJL-UHFFFAOYSA-N; MolPort-003-943-662; ZINC4370978; ZX-AN037609; ALBB-022022; CCG-43794; STL482580; RJF 00091; BDBM50100971; AKOS003623024; MCULE-3366928787; CCG-245923; Biguanidine, 1-(3,5-dichlorophenyl)-; NCGC00331378-01
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 558969
TTD: D0R9AD
 Compound Name C[-Arg-Gly-Asp-Acpca22-] Investigative [15]
Synonyms
CHEMBL539850
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11540715
TTD: D0R9GW
 Compound Name ST-1646 Investigative [17]
Synonyms
CHEMBL392303
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44439175
TTD: D0R9SJ
 Compound Name Cyclo[RGDfK(cypate)] Investigative [18]
Synonyms
CHEMBL407126
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44409643
TTD: D0T1II
 Compound Name 3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid Investigative [16]
Synonyms
CHEMBL220128; BDBM50323318; 3-phenyl-3-(3-(1,2,3,4-tetrahydroisoquinolin-7-ylcarbamoyl)benzamido)propanoic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44418281
TTD: D0TP8S
 Compound Name Cyclo-[-Arg-Gly-Asp-Amp27-] Investigative [17]
Synonyms
CHEMBL272436
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44456982
TTD: D0U0VF
 Compound Name C[RGD-(R)-alpha-TfmfV] Investigative [13]
Synonyms
CHEMBL377066
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44408397
TTD: D0U2NV
 Compound Name C-[-Arg-Gly-Asp-Acpca33-] Investigative [15]
Synonyms
CHEMBL534712
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11670104
TTD: D0UE7H
 Compound Name Cypate-[(RGD)3-NH2]2 Investigative [18]
MOA Inhibitor
External Link
CID: 91936296
TTD: D0UO0Y
 Compound Name C[RGD-(S)-alpha-TfmfV] Investigative [13]
Synonyms
CHEMBL379056
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9986643
TTD: D0V0JC
 Compound Name C[-Arg-Gly-Asp-Acpca20-] Investigative [15]
Synonyms
CHEMBL540618
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11656381
TTD: D0W6CJ
 Compound Name C[RGDf-(S,R)-alpha-Dfm-F] Investigative [13]
Synonyms
CHEMBL379911
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11614485
TTD: D0WK2F
 Compound Name AcDRGDS Investigative [26]
Synonyms
CHEMBL241297; Acetyl-Asp-Arg-Gly-Asp-Ser-OH
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10415998
TTD: D0X4EE
 Compound Name Cypate-[(RGD)4-NH2]1 Investigative [18]
MOA Inhibitor
External Link
CID: 91936299
TTD: D0Y8UD
 Compound Name Cyclo-[-Arg-Gly-Asp-Amp23-] Investigative [17]
Synonyms
CHEMBL410050
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 24822282
TTD: D0Z6WZ
 Compound Name SB-265123 Investigative [27]
Synonyms
CHEMBL288493; SCHEMBL244383; HODBWQCCKYDYPY-NRFANRHFSA-N; {3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; BDBM50078714; {(S)-3-[3-(Pyridin-2-ylamino)-propoxy]-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-10-yl}-acetic acid; (S)-10,11-Dihydro-3-[3-(pyridin-2-ylamino)-1-propyloxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9952958
TTD: D0R3CY
 Compound Name C(-GRGDfL-) Investigative [28]
Synonyms
CHEMBL235999
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 15409414
TTD: D0B4JU
2C12: Liver cancer 49 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name 90Y-loaded resin microspheres Approved [29]
External Link
TTD: DGWE36
 Compound Name Thymalfasin Phase 2 [30]
Synonyms
Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1
    Click to Show/Hide
External Link
CID: 16130571
TTD: D0I5KX
 Compound Name Ferumoxides Approved [31]
Synonyms
AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric
    Click to Show/Hide
External Link
CID: 6432052
TTD: D08QAC
DrugBank: DB06215
 Compound Name DTI-015 Approved [32]
Synonyms
Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics
    Click to Show/Hide
External Link
CID: 2578
TTD: D01OXI
DrugBank: DB00262
 Compound Name Nofazinlimab Phase 3 [33]
Synonyms
CS1003; EQ176
    Click to Show/Hide
External Link
TTD: DX9GT7
 Compound Name PV-10 Phase 3 [34]
Synonyms
632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium
    Click to Show/Hide
External Link
CID: 69438
TTD: D0L2VT
 Compound Name Brivanib Phase 3 [35]
Synonyms
649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol
    Click to Show/Hide
External Link
CID: 11234052
TTD: D0HS5V
DrugBank: DB11958
 Compound Name JX-594 Phase 3 [36]
Synonyms
Pexastimogene devacirepvec
    Click to Show/Hide
External Link
TTD: D0HB0V
 Compound Name ABH001 Phase 3 [37]
External Link
TTD: D05LPP
 Compound Name MTC-DOX Phase 2/3 [38]
Synonyms
MTC-doxorubicin
    Click to Show/Hide
External Link
TTD: D0W9AI
 Compound Name KD018 Phase 2 [39]
External Link
TTD: D0NB9T
 Compound Name Doxorubicin-eluting beads Phase 2 [40]
Synonyms
DC Bead (TN)
    Click to Show/Hide
External Link
TTD: D0M5CD
 Compound Name 32-P BioSilicon Phase 2 [41]
Synonyms
BrachySil
    Click to Show/Hide
External Link
TTD: D0M1YS
 Compound Name Cixutumumab Phase 2 [42]
Synonyms
LY3012217
    Click to Show/Hide
External Link
TTD: D0E5DP
 Compound Name [131I]-Metuximab Phase 2 [43]
External Link
TTD: D0E5BW
 Compound Name Darinaparsin Phase 2 [44]
Synonyms
ZIO-101
    Click to Show/Hide
External Link
CID: 11683005
TTD: D03ZME
DrugBank: DB06179
 Compound Name Tigatuzumab Phase 2 [45]
External Link
TTD: D03LTO
 Compound Name CMC-001 Phase 2 [46]
Synonyms
Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast
    Click to Show/Hide
External Link
TTD: D00WMJ
 Compound Name OBP-301 Phase 1/2 [47]
External Link
TTD: D0D8ZK
 Compound Name MBO7133 Phase 1/2 [48]
External Link
TTD: D0C3MW
 Compound Name INCB62079 Phase 1/2 [34]
External Link
TTD: D0BE8H
 Compound Name NV-1020 Phase 1/2 [49]
External Link
TTD: D0B6EA
 Compound Name DCVax-Liver Phase 1/2 [50]
Synonyms
Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics
    Click to Show/Hide
External Link
TTD: D00ESH
 Compound Name SRF388 Phase 1 [51]
External Link
TTD: DLY89F
 Compound Name ET140202 Phase 1 [52]
External Link
TTD: D4K2OF
 Compound Name ADP-A2AFP Phase 1 [53]
External Link
TTD: D31ORV
 Compound Name SM04755 Phase 1 [54]
External Link
TTD: D0P5XM
 Compound Name Anti-CEA CAR-T therapy Phase 1 [34]
External Link
TTD: D0OP1L
 Compound Name PI-166 Phase 1 [55]
External Link
TTD: D0J2YR
 Compound Name CRS-100 Phase 1 [56]
External Link
TTD: D0B4DL
 Compound Name Autologous ET1402L1-CART cells Phase 1 [57]
External Link
TTD: D09TGO
 Compound Name Anti-CD133-CAR vector-transduced T cells Phase 1 [58]
External Link
TTD: D09HRH
 Compound Name MRX34 Phase 1 [59]
External Link
TTD: D08SJY
 Compound Name ALN-VSP Phase 1 [60]
External Link
TTD: D08JMI
 Compound Name EPCAM-targeted CAR-T cells Clinical trial [61]
External Link
TTD: D0T8DD
 Compound Name ADI Discontinued in Phase 3 [62]
Synonyms
Arginine deiminase
    Click to Show/Hide
External Link
CID: 46906074
TTD: D0O4EV
 Compound Name GN-1140 Discontinued in Phase 2 [63]
External Link
TTD: D0V4CL
 Compound Name OGT-719 Discontinued in Phase 2 [64]
Synonyms
OGS-719
    Click to Show/Hide
External Link
CID: 9838997
TTD: D0C2CH
 Compound Name AFP-Scan Discontinued in Phase 2 [65]
External Link
TTD: D08CCC
 Compound Name SR1078 Preclinical [66]
Synonyms
1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2
    Click to Show/Hide
External Link
CID: 17980288
TTD: D9D6QN
 Compound Name Occlusin Preclinical [67]
Synonyms
Occlusin 50 Injection; Occlusin 500 injection
    Click to Show/Hide
External Link
TTD: D00INM
 Compound Name HRC-201 Terminated [68]
Synonyms
Hemoglobin-imaging conjugate (HepSelect), Hemosol
    Click to Show/Hide
External Link
TTD: D09ZCH
 Compound Name 1,2,3,4,5,6-hexabromocyclohexane Investigative [69]
Synonyms
1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694
    Click to Show/Hide
External Link
CID: 74603
TTD: DLW69V
 Compound Name STP-322 Investigative [70]
Synonyms
Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics
    Click to Show/Hide
External Link
TTD: D0R8KF
 Compound Name AMB-8LK Investigative [70]
Synonyms
Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma
    Click to Show/Hide
External Link
TTD: D0P2MD
 Compound Name MiR-34a mimics Investigative [70]
Synonyms
MiR-34a mimics (liver cancer)
    Click to Show/Hide
External Link
TTD: D0M9TD
 Compound Name P53 fusion protein Investigative [70]
Synonyms
P53 fusion protein (pancreatic/liver cancer)
    Click to Show/Hide
External Link
TTD: D06WLG
 Compound Name OP-05 Investigative [70]
Synonyms
OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon
    Click to Show/Hide
External Link
TTD: D02OIP
 Compound Name GR-DD1 Investigative [70]
Synonyms
Cytotoxin (hepatic metastasis), ERYtech
    Click to Show/Hide
External Link
TTD: D00QFV
References
Ref 1 The functions of N6-methyladenosine modification in lncRNAs. Genes Dis. 2020 Mar 19;7(4):598-605. doi: 10.1016/j.gendis.2020.03.005. eCollection 2020 Dec.
Ref 2 Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308. J Med Chem. 1999 Dec 16;42(25):5254-65. doi: 10.1021/jm990418b.
Ref 3 Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73. doi: 10.1021/jm000022w.
Ref 4 Non-peptide fibrinogen receptor antagonists. 3. design and discovery of a centrally constrained inhibitorc, Bioorg. Med. Chem. Lett. 4(15):1835-1840 (1994).
Ref 5 Preparation and Properties of a fibrinogen receptor antagonist containing the Arg-Gly-Asp sequence and nitroxide radicals, Bioorg. Med. Chem. Lett. 3(6):1179-1184 (1993).
Ref 6 Synthesis and antiplatelet activity of DMP 757 analogs, Bioorg. Med. Chem. Lett. 5(18):2097-2100 (1995).
Ref 7 Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation. J Med Chem. 1995 Jan 6;38(1):34-41. doi: 10.1021/jm00001a008.
Ref 8 Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis model. Bioorg Med Chem Lett. 1998 Nov 17;8(22):3171-6. doi: 10.1016/s0960-894x(98)00556-3.
Ref 9 US patent application no. 7,425,545, Modulation of C-reactive protein expression.
Ref 10 1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2619-22. doi: 10.1016/s0960-894x(01)00529-7.
Ref 11 Molecular model of the alpha(IIb)beta(3) integrin. J Med Chem. 2003 Dec 4;46(25):5316-25. doi: 10.1021/jm030146j.
Ref 12 Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists. J Med Chem. 1997 Aug 29;40(18):2843-57. doi: 10.1021/jm970020k.
Ref 13 Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study of their conformational and biological behavior. J Med Chem. 2006 Mar 9;49(5):1808-17. doi: 10.1021/jm0511334.
Ref 14 Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds. Bioorg Med Chem. 2007 Dec 1;15(23):7380-90. doi: 10.1016/j.bmc.2007.07.049. Epub 2007 Aug 22.
Ref 15 Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. doi: 10.1021/jm050698x.
Ref 16 Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7. doi: 10.1016/j.bmcl.2006.07.090. Epub 2006 Aug 21.
Ref 17 Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. doi: 10.1021/jm701214z. Epub 2008 Feb 28.
Ref 18 Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. doi: 10.1021/jm050947h.
Ref 19 Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005 Feb 24;48(4):1098-106. doi: 10.1021/jm049165z.
Ref 20 alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers. J Med Chem. 2009 Nov 26;52(22):7029-43. doi: 10.1021/jm901133z.
Ref 21 Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem. 2006 Jun 1;49(11):3416-20. doi: 10.1021/jm060233m.
Ref 22 Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5227-32. doi: 10.1016/j.bmcl.2004.06.061.
Ref 23 Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics. J Med Chem. 2010 Jan 14;53(1):106-18. doi: 10.1021/jm9013532.
Ref 24 N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem. 1999 Aug 12;42(16):3033-40. doi: 10.1021/jm970832g.
Ref 25 Emerging targets in osteoporosis disease modification. J Med Chem. 2010 Jun 10;53(11):4332-53. doi: 10.1021/jm9018756.
Ref 26 Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2329-33. doi: 10.1016/j.bmcl.2007.01.073. Epub 2007 Jan 27.
Ref 27 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5937-41. doi: 10.1016/j.bmcl.2004.08.067.
Ref 28 Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81. doi: 10.1021/jm701044r. Epub 2007 Nov 1.
Ref 29 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
Ref 30 ClinicalTrials.gov (NCT01031966) A Pilot Study to Evaluate ZADAXIN's (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine. U.S. National Institutes of Health.
Ref 31 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 32 Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62.
Ref 33 ClinicalTrials.gov (NCT04194775) A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC). U.S.National Institutes of Health.
Ref 34 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 35 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5671).
Ref 36 ClinicalTrials.gov (NCT02017678) Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin. U.S. National Institutes of Health.
Ref 37 ClinicalTrials.gov (NCT01749306) A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing. U.S. National Institutes ofHealth.
Ref 38 ClinicalTrials.gov (NCT00034333) Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer. U.S. National Institutes of Health.
Ref 39 ClinicalTrials.gov (NCT00730158) A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
Ref 40 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026037)
Ref 41 PRODUCTS: BrachySil. Psivida corp
Ref 42 ClinicalTrials.gov (NCT01232452) A Study in Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 43 ClinicalTrials.gov (NCT00819650) A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection. U.S. National Institutes of Health.
Ref 44 ClinicalTrials.gov (NCT00421213) Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers. U.S. National Institutes of Health.
Ref 45 ClinicalTrials.gov (NCT01307891) Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer. U.S. National Institutes of Health.
Ref 46 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021589)
Ref 47 ClinicalTrials.gov (NCT02293850) Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma. U.S. National Institutes of Health.
Ref 48 Clinical pipeline report, company report or official report of Metabasis Therapeutics (2006).
Ref 49 ClinicalTrials.gov (NCT00149396) Safety and Efficacy of a Genetically Engineered Herpes Simplex Virus NV1020 to Treat Colorectal Cancer Metastatic to Liver. U.S. National Institutes of Health.
Ref 50 ClinicalTrials.gov (NCT01882946) Safety and Efficacy Study of DCVax-Direct in Solid Tumors. U.S. National Institutes of Health.
Ref 51 ClinicalTrials.gov (NCT04374877) Study of SRF388 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 52 ClinicalTrials.gov (NCT03965546) Clinical Study of ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Advanced Liver Cancer. U.S.National Institutes of Health.
Ref 53 ClinicalTrials.gov (NCT03132792) A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFP????T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types. U.S.National Institutes of Health.
Ref 54 ClinicalTrials.gov (NCT02191761) Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer. U.S. National Institutes of Health.
Ref 55 Clinical pipeline report, company report or official report of Progen.
Ref 56 ClinicalTrials.gov (NCT00327652) Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases. U.S. National Institutes of Health.
Ref 57 ClinicalTrials.gov (NCT03349255) Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
Ref 58 ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
Ref 59 ClinicalTrials.gov (NCT01829971) A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection. U.S. National Institutes of Health.
Ref 60 Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011).
Ref 61 ClinicalTrials.gov (NCT02729493) Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer
Ref 62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003116)
Ref 63 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015394)
Ref 64 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009854)
Ref 65 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008092)
Ref 66 Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
Ref 67 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018427)
Ref 68 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020214)
Ref 69 Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. J Nutr. 2007 Nov;137(11):2366-70.
Ref 70 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.